Shares are trading at $2.24 which is slightly above $2.06, the 50 day moving average and marginally over the 200 day moving average of $2.05. The 50 day moving average was up $0.18 and the 200 day average moved up $0.19. 689K shares changed hands in the last trading session. Trading volume was down 45.10% under the stocks average daily volume.
Short traders are more bearish on the company if you take a look at the motion in short interest. The company saw a rise in short interest between September 29, 2017 and October 13, 2017 of 3.12%. Short interest increased from 1,760,967 to 1,815,979 over that period. With short interest at 1,815,979 and short average daily volume at 934,837, days to cover is 2.0 and the percentage of shorted shares was 0.19% on October 13.
These funds have shifted positions in (HTGM). Blackrock Inc. reduced its holdings by selling 1,543 shares a decrease of 71.9% from 03/31/2017 to 06/30/2017. Blackrock Inc. currently owns 602 shares valued at $2,000. The value of the position overall is down by 86.7%. As of quarter end Novo A/s had disposed of 49,786 shares trimming its position 3.9%. The value of the total investment in HTG Molecular Diagnostics, Inc. decreased from $8,859,000 to $3,273,000 a change of $5,586,000 quarter over quarter.
As of the end of the quarter Ubs Group Ag had sold a total of 18,718 shares trimming its stake by 94.7%. The value of the company’s investment in HTG Molecular Diagnostics, Inc. went from $137,000 to $3,000 a change of 97.8% for the reporting period. Sonora Investment Management, LLC grew its position by buying 2,000 shares an increase of 57.1% as of 09/30/2017. Sonora Investment Management, LLC controls 5,500 shares worth $9,350,000. The total value of its holdings increased 0.4%.
As of the latest earnings report the EPS was $-2.95 and is projected to be $-2.29 for the current year with 11,448,000 shares outstanding. Next quarter’s EPS is expected be $-0.48 with next year’s EPS anticipated to be $-1.72.
HTG Molecular Diagnostics, Inc., launched on December 14, 2000, is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Business’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Business’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Business’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument..